Raymond Debbane has been a director since 2007 and became chairman in 2012. Mr. Debbane is president and chief executive officer of The Invus Group, LLC, a company he founded in 1985 to be the exclusive investment advisor for Benelux-based Artal Group S.A. In 1999, Artal became the controlling shareholder of Weight Watchers International, Inc., for which Mr. Debbane serves as chairman of the board of directors. He also serves as chairman or director of a number of other companies in which Invus and Artal Group S.A. have invested. Before founding The Invus Group, Mr. Debbane was a manager in the Paris office of The Boston Consulting Group, Inc., where he consulted for a number of major European and international companies. Mr. Debbane holds an M.B.A. from Stanford University, an M.S. in food science and technology from the University of California at Davis, and a B.S in agricultural sciences and agricultural engineering from American University of Beirut.
Philippe J. Amouyal has been a director since 2007 and is a managing director of The Invus Group, LLC, a position he has held since 1999. Previously, Mr. Amouyal was a vice president and director of The Boston Consulting Group, Inc., where he coordinated the global technology and electronics practice through most of the 1990s. Mr. Amouyal is a director of Weight Watchers International, Inc., as well as of a number of other companies in which Invus has invested. He holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris, and was a research fellow at the Center for Policy Alternatives at the Massachusetts Institute of Technology.
Samuel L. Barker, Ph.D., has been a director since 2000 and served as chairman from 2005 to 2012. Dr. Barker held a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999, including executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Previously, Dr. Barker held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. He received a B.S. from Henderson State College, an M.S. from the University of Arkansas, and a Ph.D. from Purdue University.
Mr. Coats has served as president, chief executive officer and director since July 2014. Previously, he served for 18 years in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, most recently as chief executive officer and president and chief operating officer. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats received a B.P.A.from Oakland University.
Robert J. Lefkowitz, M.D., has been a director since 2001 and a consultant to Lexicon since 2003. Dr. Lefkowitz is the James B. Duke Professor of Medicine, professor of biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry, the Shaw Prize, the Albany Medical Center Prize and the 2007 National Medal of Science. He earned a B.A. in chemistry from Columbia University and an M.D. degree from Columbia University College of Physicians and Surgeons.
Alan S. Nies, M.D., has been a director and chairman of Lexicon’s medical advisory board since 2003. Dr. Nies has more than 40 years of clinical and pharmacological experience and plays an integral advisory role in the development of Lexicon’s clinical programs. From 1992 until his retirement in 2002, Dr. Nies served in a series of senior management positions at Merck & Co. Inc., including senior vice president of clinical sciences. During his tenure at Merck, he was responsible for worldwide clinical development and clinical research, and was involved in the development of several drugs, including Fosamax, Singulair, Emend, Zetia and Vioxx. Previously, Dr. Nies spent 15 years as professor of medicine and pharmacology, and head of the Division of Clinical Pharmacology at the University of Colorado Health Sciences Center. He received a B.S. in chemistry from Stanford University and an M.D. degree from Harvard Medical School.
Frank P. Palantoni has been a director since 2004. Mr. Palantoni is chief executive officer of Laboratoire M2, a manufacturer of disinfection products. He was president of the pet and animal health division of Central Garden & Pet Company from 2011 to 2013 and was previously a partner at P3 Capital Management, an early stage consumer products equity fund. Mr. Palantoni previously held a variety of senior management positions with Novartis AG, including president and chief executive officer, worldwide of its Gerber Products Company, Novartis Infant and Baby Division, and president and chief executive officer for North American operations of Novartis Consumer Health Division. Prior to joining Novartis, he held a series of senior management positions with The Danone Group. Mr. Palantoni received his B.S. from Tufts University and his M.B.A. from Columbia University.
Christopher J. Sobecki has been a director since 2007 and is a managing director of The Invus Group, LLC, which he joined in 1989. Mr. Sobecki has served on the board of directors of numerous companies in which Invus has invested and is currently a member of the board of directors of Weight Watchers International, Inc. He holds a B.S. in industrial engineering from Purdue University and an M.B.A. from Harvard University.
Judith L. Swain, M.D. has been a director since 2007. Dr. Swain is a Senior Fellow of the Agency for Science, Technology and Research Singapore A*STAR, and Professor of Medicine at the National University of Singapore. From 2005 to 2006, she was the dean for translational medicine at the University of California, San Diego. Dr. Swain previously served as chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University. She has previously served in a number of national and international leadership roles and as a director or member of the scientific advisory boards for a number of biotechnology companies and is co-founder of Synecor, LLC. Dr. Swain received a B.S. from the University of California, Los Angeles, and an M.D. degree from the University of California, San Diego.